Pamela Wapnick

CIK: 0001995657

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (75.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

MGX

Metagenomi Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

MGX
Metagenomi Therapeutics, Inc.
Sep 8, 2026
Sale(S)
Direct
1.9K shares at avg. $1.16$2K
MGX
Metagenomi Therapeutics, Inc.
Jun 5, 2026
Sale(S)
Direct
2.9K shares at avg. $1.30$4K
MGX
Metagenomi Therapeutics, Inc.
Apr 1, 2026
Award(A)
Direct
24K shares-
MGX
Metagenomi Therapeutics, Inc.
Mar 5, 2026
Sale(S)
Direct
1.6K shares at avg. $1.60$3K
MGX
Metagenomi, Inc.
Dec 5, 2025
Sale(S)
Direct
1.6K shares at avg. $1.77$3K
MGX
Metagenomi, Inc.
Dec 1, 2025
Award(A)
Direct
120K shares at avg. $1.60$192K
MGX
Metagenomi, Inc.
Sep 5, 2025
Sale(S)
Direct
1.6K shares at avg. $1.81$3K
MGX
Metagenomi, Inc.
Jun 6, 2025
Sale(S)
Direct
1.6K shares at avg. $1.75$3K
MGX
Metagenomi, Inc.
Apr 1, 2025
Award(A)
Direct
14K shares-
MGX
Metagenomi, Inc.
Mar 5, 2025
Sale(S)
Direct
1.8K shares at avg. $1.87$3K
MGX
Metagenomi, Inc.
Dec 5, 2024
Sale(S)
Direct
1.6K shares at avg. $1.86$3K
MGX
Metagenomi, Inc.
Sep 5, 2024
Sale(S)
Direct
6.3K shares at avg. $2.88$18K

		Type	Shares	Price		Ownership
Sep 8, 2026	MGX Metagenomi Therapeutics, Inc.	Sale(S)	1,911	$1.16	$2,214	Direct
Jun 5, 2026	MGX Metagenomi Therapeutics, Inc.	Sale(S)	2,884	$1.30	$3,746	Direct
Apr 1, 2026	MGX Metagenomi Therapeutics, Inc.	Award(A)	24,000	-	$0	Direct
Mar 5, 2026	MGX Metagenomi Therapeutics, Inc.	Sale(S)	1,581	$1.60	$2,530	Direct
Dec 5, 2025	MGX Metagenomi, Inc.	Sale(S)	1,576	$1.77	$2,793	Direct
Dec 1, 2025	MGX Metagenomi, Inc.	Award(A)	120,000	$1.60	$192,000	Direct
Sep 5, 2025	MGX Metagenomi, Inc.	Sale(S)	1,576	$1.81	$2,853	Direct
Jun 6, 2025	MGX Metagenomi, Inc.	Sale(S)	1,576	$1.75	$2,758	Direct
Apr 1, 2025	MGX Metagenomi, Inc.	Award(A)	14,000	-	-	Direct
Mar 5, 2025	MGX Metagenomi, Inc.	Sale(S)	1,808	$1.87	$3,390	Direct
Dec 5, 2024	MGX Metagenomi, Inc.	Sale(S)	1,559	$1.86	$2,900	Direct
Sep 5, 2024	MGX Metagenomi, Inc.	Sale(S)	6,265	$2.88	$18,043	Direct

1-12 of 12 transactions

About Wapnick Pamela

Wapnick Pamela (SEC CIK 0001995657) files insider reports with the SEC as Chief Financial Officer of Metagenomi Therapeutics, Inc. (MGX).

Signal8 holds 11 ownership filings by Wapnick Pamela, all Form 4s, filed between Sep 6, 2024 and Sep 10, 2026. Those filings report 12 transactions, from Sep 5, 2024 to Sep 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Wapnick Pamela's filings is in EMERYVILLE, CA.

Recent filings by Wapnick Pamela

Sep 8, 2026: Open-market sale of MGX shares (Form 4, code S).
Jun 5, 2026: Open-market sale of MGX shares (Form 4, code S).
Apr 1, 2026: Grant or award of MGX shares (Form 4, code A).
Mar 5, 2026: Open-market sale of MGX shares (Form 4, code S).
Dec 5, 2025: Open-market sale of MGX shares (Form 4, code S).

Other insiders filing for Metagenomi Therapeutics, Inc. (MGX)

How to read Form 4 transaction codes